Alt Data Coming Soon – Stay Tuned! Subscribe to our Newsletter for instant updates and access. Have ideas? Submit feedback to help us improve.
Loading...

Regeneron Pharmaceuticals, Inc.

REGNNASDAQ
Healthcare
Biotechnology
$563.10
$-1.54(-0.27%)

Regeneron Pharmaceuticals, Inc. (REGN) Stock Overview

Explore Regeneron Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 79.9/100

Key Financials

Market Cap59.8B
P/E Ratio13.44
EPS (TTM)$39.32
ROE0.15%
Fundamental Analysis

AI Price Forecasts

1 Week$447.20
1 Month$536.61
3 Months$651.24
1 Year Target$882.65

REGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Regeneron Pharmaceuticals, Inc. (REGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 58.25, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $882.65.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 13.44 and a market capitalization of 59.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;